Back to search results

The MedMemos Study: Promoting Medication Adherence in Pediatric Bone Marrow Transplant Patients

This study, called MedMemos, is testing a new way to help parents and children take their medications correctly after a bone marrow transplant (hematopoietic cell transplant). The MedMemos program includes four sessions with educational videos and a "Medication Management Kit" to help families overcome challenges with taking medicines. We want to see if families find MedMemos helpful and easy to use, and if it helps children take their medications better. Children aged 0 to 12 years who have had a bone marrow transplant and are still in the hospital can join if their caregiver is willing to participate. We plan to enroll 25 participants.

Study design
This is an interventional study, meaning participants will receive the MedMemos program. It aims to enroll 25 participants.
What's involved
Participants will complete surveys, attend 4 intervention sessions, and use an electronic box or pill bottle to store their medications.
Compensation
Not stated in the trial record.
Follow-up
Intervention acceptability will be measured around 14-28 days after hospital discharge. Completion rates will be monitored throughout the study, with final rates reported after follow-ups are complete, estimated around Month 11 of Year 2.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07718204

The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients

Recruiting
NAAges 0–12InterventionalSupportive care
Nationwide Children's Hospital
~25 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:MedMemos

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Intervention Acceptability
Measured over At the end of session 4 (An average of 14 days following the patient's hospital discharge, up to 28 days following discharge)
+3 more outcomes measured

Conditions

Hematopoietic Cell Transplant

Explore related trials

Hematopoietic Cell Transplantation

Where it's being run

1 sites across 1 states
Ohio1

Who to contact

Ahna LH Pai, PhD
[email protected]
(614) 938-1601
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Child had a Pediatric Allogeneic Hematopoietic Cell Transplant (PAHCT)
Child is 0-12 years of age
At the time of recruitment child is still in the hospital for PAHCT
Child's primary caregiver is responsible for administering medical care and is willing to give consent to participate
Child is prescribed an oral medication regimen at discharge

Exclusion

Caregiver does not speak English, Spanish, or Arabic
Caregiver is not available to provide written permission for the child's participation
EMR or medical team report of the caregiver's cognitive status precludes completion of questionnaires
The child's medical status or condition precludes completion of the study questionnaires as determined by the physician or caregiver
Caregiver is unwilling to store medication in an electronic monitor

What this trial measures

  • Intervention AcceptabilityAt the end of session 4 (An average of 14 days following the patient's hospital discharge, up to 28 days following discharge)

    Intervention acceptability will be demonstrated by caregivers rating MedMemos a mean of ≥ 4 as measured on Acceptability of Intervention Measure, Feasibility of Intervention Measure, and Intervention Appropriateness Measure. Each measure asks participants to rate statements on a scale of "Completely Disagree" to "Completely Agree" Higher scores indicate greater acceptability, feasibility, and appropriateness.

  • Intervention Feasibility - Percentage of patients who enroll out of those approachedEnrollment rate will be continually monitored throughout enrollment and final enrollment percentage will be calculated at the close of enrollment. Enrollment is estimated to end during Month 9 of Year 2.

    Feasibility will be assessed by calculating enrollment rate (total number of patients enrolled / total number of patients approached). Feasible enrollment will be achieved by enrolling 80% or more of eligible caregivers.

  • Intervention Feasibility - Percentage of intervention sessions and follow-ups completed by enrolled participants.Completion rates will be calculated during the study in real time as part of study monitoring. Final study completion rates will be reported after the final follow-up is complete. Follow-ups are estimated to be complete Month 11 of Year 2.

    Feasibility will be assessed by calculating the percentage of MedMemos sessions attended and the number of follow-up visits completed. Feasibility will be achieved if 80% or more of MedMemos sessions are attended by participants and if 80% or more of follow-up visits are completed by participants.

  • Intervention Feasibility - Percentage of the intervention protocol delivered by the interventionist.Intervention fidelity will be monitored in real time to maintain adherence to the intervention protocol. Final intervention fidelity will be reported after the final MedMemos session is completed. Sessions are anticipated to end in Month 11 Year 2.

    Feasibility of the intervention delivery will be assessed by calculating the intervention fidelity. Fidelity will be assessed by a member of the lab not involved in intervention delivery using a fidelity checklist developed by the study Principal Investigator. Feasibility of the intervention delivery will be achieved if fidelity checklist scores are 80% are greater (80% or more of the intervention delivered across the study)